Key result
Venous thromboembolism and cardiovascular disease commonly occur in patients with multiple myeloma, requiring careful risk stratification and appropriate prophylaxis to prevent life-threatening complications.
VTE and cardiovascular disease in multiple myeloma patients can limit tolerance to cancer treatments, highlighting the need for careful assessment and prevention.
Supports vigilance for VTE/CVD in multiple myeloma to preserve treatment tolerance; leaves open need for prospective validation of prophylaxis strategies.
BACKGROUND: Venous thromboembolism (VTE) and cardiovascular (CV) disease can occur in patients with multiple myeloma. Although VTE and CV disease are separate medical conditions, they can be serious and even life-threatening. . OBJECTIVES: The objectives of this article are to describe risk factors for cancer-associated VTE, describe the influence of CV disease on patients with multiple myeloma, and review the approaches to VTE and CV disease identification and treatment. . METHODS: PubMed and CINAHL® databases were used to identify literature to describe VTE and CV in patients diagnosed with multiple myeloma. . FINDINGS: When present in patients with multiple myeloma, VTE and CV disease can limit patient tolerance for myeloma treatment and, therefore, decrease therapeutic options.
No takes yet. Share an insight, caveat, or question.
Noonan et al. (2017) conducted a review in Multiple Myeloma. Venous thromboembolism and cardiovascular disease prevention was evaluated. Venous thromboembolism and cardiovascular disease commonly occur in patients with multiple myeloma, requiring careful risk stratification and appropriate prophylaxis to prevent life-threatening complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: